Investigation of the toxic effect of different doses of duprost on kidneys of albino mice

Benign prostatic hyperplasia (BPH) is a medical condition occurring in older men (those aged >60 years), resulting from enlargement of the prostate gland. Consequently, affected men may experience bothersome urinary tract symptoms and diminished quality of life. The risk of lower urinary tract symptoms and complications such as acute urinary retention (AUR) may increase if BPH if untreated. The active ingredient - dutasteride- inhibits the action of both forms (type I and type II) of the enzyme 5α-reductase that convert the male hormone testosterone to dihydrotestosterone (DHT) in the skin and the liver. DHT is the androgen primarily responsible for development and growth of the prostate gland and also causes (BPH). The action of dutasteride is to reduce the levels of DHT in the blood, so that prostate growth is no longer stimulated in men with BPH allowing the enlarged prostate to shrink. The 5alpha-reductase inhibitor was shown to reduce the risk of retention and surgery in men with large prostate volumes and/or high PSA. Recent studies have examined the role of adding an alpha1-blocker to 5alpha-reductase inhibitor in short- or long-term combination. The 5 alpha-reductase inhibitor provides a logical medical treatment for benign prostatic hyperplasia. However, the effects of chronic treatment on prostatic androgen levels, 5 alpha-reductase activity, tissue prostatic specific antigen (PSA) as well as other organs have not been studied.

Author(s): Ban Jasim Mohamad

Abstract | PDF

Share This Article